Section 3 of 6
Product information and disease description
307 evidence topics · 144 sources
Product description
Phase of product development
FDA regenerative medicine advanced therapy designation
Designations covering both wet AMD and diabetic macular edema
4FRONT-1 enrollment completion and expected topline data
4FRONT-2 enrollment completion and expected topline data
Phase 3 design alignment with FDA, EMA, and Japan Pharmaceuticals and Medical Devices Agency
Biologics license application submission date, marketing authorization application, and approval dates
No evidence found.
Regulatory status
No evidence found.
Launch
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: 4D Molecular Therapeutics
Nonproprietary name, brand name, and code name
No evidence found.
Therapeutic class: intravitreal AAV gene therapy expressing anti-VEGF biologics
Dosage forms and strengths
Doses studied in clinical trials
Dose levels evaluated in the diabetic macular edema trial
Commercial formulation, container, and storage conditions
No evidence found.
Average sales price and wholesale acquisition cost
Summary: comparator Medicare Part B payment limits
No price, average sales price, or wholesale acquisition cost has been announced for 4D-150. For intravitreal anti-VEGF comparators, Medicare Part B payment limits effective July 1 to September 30, 2026 (based on first-quarter 2026 ASP data) were $743.605 per 1 mg for aflibercept (J0178), $298.683 per 1 mg for aflibercept HD (J0177), $803.255 per 1 mg for aflibercept-ayyh (Q5147), $32.381 per 0.1 mg for faricimab-svoa (J2777), $51.090 per 0.1 mg for ranibizumab (J2778), $240.972 per 0.1 mg for ranibizumab-nuna (Q5124), $82.528 per 0.1 mg for ranibizumab-eqrn (Q5128), $74.795 per 0.1 mg for ranibizumab via the Susvimo implant (J2779), $359.713 per 1 mg for brolucizumab-dbll (J0179), and $74.823 per 10 mg for bevacizumab (J9035), each with 20% coinsurance. At labeled nAMD doses these limits correspond to $1,487.21 per aflibercept 2 mg injection, $1,606.51 per aflibercept-ayyh 2 mg injection, $2,389.46 per aflibercept 8 mg injection, $1,942.86 per faricimab 6 mg injection, $255.45 per ranibizumab 0.5 mg injection, and $2,158.28 per brolucizumab 6 mg injection (calculated).
Sponsor statements on anticipated pricing of 4D-150
Comparator wholesale acquisition costs: aflibercept 8 mg and faricimab, 2025
“Direct costs were estimated based on modeled mean injection numbers and 2025 wholesale acquisition costs per injection (aflibercept 8 mg: 2677.50 USD; faricimab: 2289.65 USD) plus medical monitoring costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator Medicare Part B average spending per claim, 2025
| HCPCS code | Brand name | Average spending per claim, 2025 (Q1-Q4) |
|---|---|---|
| J0178 | “EYLEA” | “1792.4254857” |
| J0177 | “EYLEA HD” | “3006.5947467” |
| Q5147 | “PAVBLU” | “2010.6720252” |
| J2777 | “VABYSMO” | “2390.9037697” |
| J2778 | “LUCENTIS” | “542.43913909” |
| Q5128 | “CIMERLI” | “880.821349” |
| Q5124 | “BYOOVIZ” | “706.41442336” |
| J2779 | “SUSVIMO” | “7460.7805379” |
| J0179 | “BEOVU” | “2267.6140542” |
Wholesale acquisition cost of a one-time ocular gene therapy: voretigene neparvovec
Average sales price methodology for physician-administered agents under Medicare Part B
Effect of billing code attribution on reported reimbursement per bevacizumab injection
“In our primary analysis, unspecified codes (e.g., J3490, J3590, and J7999) were attributed to bevacizumab based on established billing precedent. Sensitivity analyses excluding these codes demonstrated that mean reimbursement remained stable at approximately $50 per injection, consistent with historical pricing patterns.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, the observed increase in reimbursement in later years likely reflects coding attribution and billing structure rather than true changes in drug cost, clinical demand, or therapeutic preference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
American hospital formulary service (AHFS), or other drug classification
WHO ATC classification of ocular antineovascularisation agents
| ATC code | Quoted entry |
|---|---|
| S01L | “OCULAR VASCULAR DISORDER AGENTS” |
| S01LA | “Antineovascularisation agents” |
| S01LA05 | “aflibercept” |
| S01LA09 | “faricimab” |
AHFS class and ATC code assigned to 4D-150
No evidence found.
Indication
Population studied in 4FRONT-1
Approved indication and labeled population
Not applicable.
Pharmacology
Mechanism of action
Dual-transgene payload delivered by an evolved AAV capsid
“We then engineered 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Directed evolution of the R100 capsid in nonhuman primates
“We implemented a directed evolution strategy that used genetic diversification and selection processes to invent a novel AAV capsid (R100) with the capacity to transduce all major cell types across all regions of the primate retina, including the macula, following IVT administration at relatively low doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After round 6, the R100 peptide insertion sequence motif represented approximately 70% of all remaining capsid sequences” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capsid structure and mechanism of inner limiting membrane penetration
“Structure–function analyses demonstrated that the 10-amino-acid peptide insertion at position R588 in the R100 capsid reduces heparin binding affinity and facilitates transit through the heparan sulfate-rich ILM, suggesting a putative mechanism for enhanced delivery to cells within the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“4D-R100 was similarly engineered from an AAV2 backbone through in vivo screening in NHPs, incorporating a 10–amino acid insertion (LAISDQTKHA) at residue 588 and a VP1 point mutation at position 34 (Pro→Ala).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for targeting VEGF-C
Promoter used in the 4D-150 transgene cassette
No evidence found.
Glycan interactions and the retinal cell types transduced by the R100 capsid
“These modifications reduce HSPG affinity and promote alternative glycan interactions (notably sialic acid), facilitating enhanced ILM penetration and efficient retinal transduction across RPE, photoreceptors, and RGCs from macula to periphery following IVT administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Human retinal pigment epithelial cells in vitro: VEGF-A neutralization and VEGF-C suppression
“Transduction of human retinal pigment epithelial cells in vitro by 4D-150 resulted in dose-dependent transgene expression and corresponding reductions in VEGF-A and VEGF-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 4D-150 plasmid cassette significantly reduced endothelial cell proliferation compared to the CAG-GFP plasmid and shock controls (1-way ANOVA, P < 0.01), whereas CAG-AFLB alone did not” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonhuman primates: intraocular aflibercept and microRNA expression
“Mean 4D-150 aflibercept transgene product levels were nearly 8-fold higher in the retina/choroid (mean ±SD = 22,518 ± 24,981 ng aflibercept/g of tissue) compared to the aqueous humor (2,919 ± 2,366 ng aflibercept/mL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, VEGF-C miRNA expression was detected (up to 91,910 copies per input RNA) from RNA isolated throughout the retina, including the superior, nasal, central, temporal, and inferior regions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonhuman primates: aqueous aflibercept concentrations by dose and construct
“Analysis of free aflibercept protein concentration in aqueous humor samples collected 21 days after dosing showed a dose response between the highest dose (1 × 1012 vg/eye) and the 2 lower doses (3 × 1011 and 1 × 1011 vg/eye) of 4D-150” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, IVT administration of 4D-150 to NHPs resulted in significantly higher levels of aflibercept protein in aqueous humor samples compared to an equivalent dose of the single-transgene construct (R100.CAG-AFLB), suggesting that the VEGF-C RNAi transgene or its position within the transgene cassette promotes aflibercept expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonhuman primate laser-induced choroidal neovascularization model
“At 2 weeks post laser administration, a significant reduction in the incidence of grade IV CNV lesions was observed at all tested doses of 4D-150 compared to vehicle (Fisher's Exact Prob test, P < 0.005 for all comparisons).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CNV complex area was significantly smaller in the 4D-150–treated groups compared to the vehicle group (52%–62% reduction; 2-way ANOVA followed by Tukey-Kramer Honestly Significant Difference (HSD), P < 0.005 for all comparisons; Fig. 7C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lowest tested dose of 4D-150 (1 × 1011 vg/eye) conferred equivalent protection against CNV compared to the highest dose (1 × 1012 vg/eye).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of transgene expression in nonhuman primates
“Transgene expression was detected as early as week 1 and increased markedly by week 3. Expression increased further between weeks 3 and 8 and was stably maintained until the final assessment 6 months after administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous aflibercept concentrations and VEGF suppression measured in participants
No evidence found.
Pharmacokinetics
Systemic exposure to the transgene product in nonhuman primates
“Serum aflibercept concentrations were below the lower limit of quantitation in all animals and at all time points in the 1 × 1011 vg/eye dose group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low concentrations of aflibercept were detected in serum in 2 of 7 animals in both the 3 × 1011 and 1 × 1012 vg/eye dose groups; of these, only one animal in the 3 × 1011 vg/eye treatment group had quantifiable levels at more than one time point” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intraocular distribution assessed in nonhuman primates
“Cynomolgus macaques (age = 6 years) received bilateral IVT injections of 4D-150 1 × 1012 vg/eye.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secreted free aflibercept was detected in all tissue samples from all ocular compartments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vector shedding assessment in the PRISM clinical trial
Clinical pharmacokinetics, shedding results, and immunogenicity results in participants
No evidence found.
Cell-based infectivity assay for transduction-competent vector in serum
Assay readout targeted to the transgene cassette
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, boxed warnings, and REMS
Not applicable.
Intraocular inflammation observed in the PRISM clinical trial
Events not observed in the clinical program to date
Dose-related ocular inflammation in nonhuman primates
“A dose response was observed for white blood cells in the aqueous and vitreous humor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 1 × 1011 vg/eye, no inflammation was observed in any eyes (0/14) in either the aqueous or vitreous humor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypotony was not observed in any 4D-150–treated eyes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Class risks described for AAV gene therapy in neovascular AMD
“Potential risks of gene therapy include a potential immune response that may be elicited by the vector, accidental activation of oncogenes or inactivation of tumor suppresor genes leading to malignant transformation via insertational mutagenesis and integration of the viral DNA inserts into the host's DNA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although AAV vectors typically support long-term and well-tolerated protein production, excessive or ectopic expression can disrupt retinal homeostasis or trigger immune-mediated inflammation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One of the most significant limitations is the presence of preexisting NAbs against AAV capsids in the human population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dependence of intraocular inflammation on vector dose and route of delivery
“Inflammation is dependent on the dose and delivery routes of the vector.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The AAV capsid leads to a dose-related humoral immunity response and antigen-specific T cell activation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of injection sites, the subretinal space is the least immunogenic followed by the suprachoroidal and ending with the vitreous cavity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, because IVT administration inherently relies on passive diffusion of AAV particles within the vitreous, achieving therapeutically relevant transduction generally necessitates the use of high vector doses. This requirement, in turn, increases the likelihood of dose-dependent ocular inflammation and systemic immune activation, which remain key safety considerations in the clinical application of this route” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dilution of the vector in the vitreous and the dose required for intravitreal delivery
“First, once the vector and its cargo are injected into the vitreous, dilution of the vector occurs. Therefore a higher dose has to be injected to compensate for this dilution effect. A higher dose may elicit a stronger immune response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Episomal persistence of the AAV genome and the risk of insertional mutagenesis
“In addition, AAV genomes rarely integrate into the host genome, thereby minimizing the risk of insertional mutagenesis, and instead persist as stable episomal forms that enable long-term transgene expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transgene overexpression as a dose-related risk and the limits on expression control
“Another important consideration is the risk of toxicity from transgene overexpression, especially when high vector doses are needed to reach therapeutic levels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This risk is heightened by the limited packaging capacity of AAV vectors, which constrains the use of complex regulatory elements that could otherwise fine-tune expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preexisting capsid antibodies, treatment eligibility, and re-dosing
“These antibodies, which may arise from natural exposure to wild-type AAVs, can neutralize the vector before it reaches target tissues, reducing transduction efficiency and potentially rendering patients ineligible for treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, a single exposure to an AAV vector can prime the immune system, complicating future re-dosing efforts and raising safety concerns” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular compartmentalization and the age of the treated population as modifiers of immune risk
“Fortunately in ocular gene therapy, the therapeutic gene is compartmentalized to the eye. Smaller doses of genetic material need to be delivered minimizing systemic side effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, the patient population affected by NV-AMD is typically an older population. This may represent an advantage since aging individuals may not mount an exuberant immune response” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose-related inflammation after intravitreal AAV aflibercept delivery in nonhuman primates
Special populations
Ocular comorbidity exclusions
Systemic condition exclusions relevant to immune and cardiovascular risk
Pediatric use, pregnancy and lactation, renal and hepatic impairment, and use in participants with pre-existing antibodies to the capsid
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on 4D-150
Prophylactic corticosteroids administered with 4D-150
Formal drug interaction studies
No evidence found.
Effects of 4D-150 on other drugs
Formal drug interaction studies
No evidence found.
Dosing and administration
Dosage
Single administration at the Phase 3 dose
Supplemental anti-VEGF injections after dosing
Redosing, dose modification, and dosing of the fellow eye
No evidence found.
Administration
Route and care setting
Topical corticosteroid prophylaxis regimen in the PRISM clinical trial
Access and distribution
Manufacturing capabilities and commercial supply
Commercial rights in Asia-Pacific markets
Expanded access program, specialty distribution, and site qualification requirements
No evidence found.
Co-prescribed/Concomitant therapies
Supplemental aflibercept in the Phase 3 trials
Concomitant ocular treatments excluded in 4FRONT-2
Corticosteroid use after the prophylactic taper
Effect of 4D-150 on quality measures
Medicare quality measure for age-related macular degeneration
Effect of 4D-150 on quality measures
No evidence found.
Product comparison
Summary: comparison with other gene therapies and long-acting anti-VEGF agents in neovascular AMD
No head-to-head trial has compared 4D-150 with another gene therapy for neovascular AMD. The three most advanced AAV programs differ in capsid, route, and dose. 4D-150 uses the synthetic R100 capsid, is given as a single intravitreal injection at 3E10 vg/eye in the Phase 3 4FRONT trials, and carries two transgenes, a codon-optimized aflibercept sequence and a microRNA targeting VEGF-C. ABBV-RGX-314 (surabgene lomparvovec) uses an AAV8 vector encoding an anti-VEGF antibody fragment and is delivered by subretinal surgery in the ATMOSPHERE (671 participants enrolled) and ASCENT (735 participants enrolled) trials, with suprachoroidal delivery in earlier-phase studies. Ixoberogene soroparvovec uses the AAV2.7m8 capsid and intravitreal delivery of aflibercept, with 6E10 vg/eye selected for the Phase 3 ARTEMIS trial (311 participants enrolled). All three Phase 3 programs use a noninferiority comparison against a bolus anti-VEGF comparator: aflibercept 2 mg every 8 weeks for 4FRONT-1, 4FRONT-2, ASCENT, and ARTEMIS, and ranibizumab 0.5 mg monthly for ATMOSPHERE. Reported intraocular inflammation differs by program and prophylaxis: 2 of 71 participants (2.8%) dosed with 4D-150 at 3E10 vg/eye had mild inflammation within 28 weeks and none thereafter, while inflammation with ixoberogene soroparvovec was managed with topical corticosteroids and drove selection of a lower dose with topical-only prophylaxis, and about 23% of participants in a suprachoroidal ABBV-RGX-314 cohort had mild inflammation. Approved long-acting comparators remain repeat-administration products: aflibercept 8 mg is dosed every 4 weeks for three doses then every 8 to 16 weeks, faricimab 6 mg is dosed every 4 weeks for four doses then at intervals up to 16 weeks, and ranibizumab delivered by the Susvimo ocular implant requires surgical implantation and refill-exchange every 24 weeks, with a boxed warning for endophthalmitis.
Sponsor view of competing late-stage gene therapy programs
Capsid, route, and transgene of competing AAV programs
“RGX-314 is one of the most advanced candidates, employing an AAV8 vector to deliver a transgene encoding an anti-VEGF antibody fragment analogous to ranibizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ADVM-022 (ixoberogene soroparvovec; Ixo-vec) employs an engineered AAV2.7m8 capsid for IVT delivery of aflibercept to suppress multiple angiogenic pathways” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on these findings, the 6 × 10¹⁰ vg/eye dose combined with topical-only prophylaxis was selected for the pivotal Phase III program” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inflammation reported with suprachoroidal and intravitreal competitor programs
“Early interim data from Cohorts 1 and 2 (2.5 × 10¹¹ and 5.0 × 10¹¹ vg/eye) showed no drug-related serious ocular adverse events, with mild intraocular inflammation occurring in approximately 23% of patients and resolving with topical corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse event was mild-to-moderate anterior segment inflammation, generally responsive to topical corticosteroids, underscoring the need for steroid co-administration and vector dose or formulation optimization” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design of the ixoberogene soroparvovec Phase 3 trial
Registered design of the ABBV-RGX-314 Phase 3 trials
Approved long-acting anti-VEGF agents: labeled dosing
Port delivery system: labeled administration and boxed warning
Vorolanib intravitreal insert: mechanism, delivery, and Phase 3 LUGANO and LUCIA design
LUGANO Phase 3 results: primary endpoint, treatment burden, safety, and LUCIA data timing
Axitinib intravitreal implant: mechanism, delivery, and Phase 3 SOL-1 and SOL-R design
SOL-1 Phase 3 results: primary endpoint, rescue-free rates, safety, and SOL-R data timing
Procedural requirements and complications of the subretinal and intravitreal routes
“However, this method is inherently invasive, requiring pars plana vitrectomy, a surgical procedure in which the vitreous gel inside the eye is removed to access the retina, and specialized surgical expertise, and may lead to serious complications such as vitreous hemorrhage and retinal detachment when performed under nonstandard conditions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For instance, intravitreal injections have a safer profile than subretinal injections. They can be performed in out patient clinics with topical anesthesia. Panretinal transduction with the genetic vector is also possible. The main disadvantages of an intravitreal injection include a potential immune response and incomplete vector penetration through the ILM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose thresholds for expression and burden reduction in the subretinal ABBV-RGX-314 program
“In the Phase I/IIa SR dose-escalation trial, higher-dose cohorts (≥6 × 10¹⁰ vg/eye) maintained protein expression for up to 2 years, with stable best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and required 59–85% fewer anti-VEGF injections compared with baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequent dose expansion to 1.0 × 10¹² vg/eye (dose level 3) maintained a consistent safety profile and yielded an ≈80% reduction in annualized injection frequency, with 50% of eyes remaining injection-free at 6 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Retinal pigmentary changes after subretinal delivery of ABBV-RGX-314
“Almost 70% of patients developed retinal pigmentary changes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These retinal pigmentary changes typically were seen in the inferior retinal periphery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intraocular aflibercept concentration after AAV delivery compared with bolus injection
Ocular adverse events reported in the ixoberogene soroparvovec Phase 1 trial
“The most common adverse events recorded was a dose dependent intraocular inflammatory response manifested by cellularity in the anterior chamber and the vitreous cavity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Some eyes developed asymptomatic pigment dispersion, segmental iris atrophy and transillumination iris defects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clinical, tomographic or angiographic evidence of retinal vasculitis, retinitis or choroiditis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Onset window for inflammation and its control in the ixoberogene soroparvovec Phase 2 trial
Place of product in therapy
Disease description
Definition and etiology
Definition: spectrum of macular disorders with neovascular and atrophic late stages
“Age-related macular degeneration is a process by which the structure and function of the macula deteriorates over time in association with distinguishing signs and symptoms that typically become evident clinically beyond 50 years of age and do not seem to be secondary to other processes such as pathologic myopia, central serous chorioretinopathy, monogenetic inherited retinal disease, chorioretinal uveitic syndromes or infections, or trauma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multifactorial etiology: complement, lipid, angiogenic, and inflammatory pathways
“Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: age, smoking, ancestry, and genetic factors
“Increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD showed strong and consistent associations with late AMD. Risk factors with moderate and consistent associations were higher body mass index, history of cardiovascular disease, hypertension, and higher plasma fibrinogen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic risk: CFH Y402H and ARMS2 A69S genotypes
“Overall, we included 6676 neovascular AMD cases and 7668 controls. Pooled overall odds ratios (ORs) (95% CI) for neovascular AMD/control were ARMS2 A69S: OR = 2.35 (2.01-2.75) for GT versus GG; OR = 8.57 (6.91-10.64) for TT versus GG; CFH Y402H: OR = 1.94 (1.73-2.18) for CT versus TT; OR = 4.89 (3.96-6.05) for CC versus TT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tobacco as a modifiable contributor to global burden
Hallmark lesion and etiologic interplay of ageing, environment, and genetic susceptibility
“AMD is characterized by accumulation of extracellular deposits, namely drusen, along with progressive degeneration of photoreceptors and adjacent tissues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AMD is a multifactorial disease encompassing a complex interplay between ageing, environmental risk factors and genetic susceptibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Neovascular age-related macular degeneration
United States incidence: meta-analysis in White Americans aged 50 years or older
“Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Late AMD incidence was 38% higher in women vs men (95% credible interval 6%, 82%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: Medicare beneficiaries aged 65 years or older
“Overall, the 3-year incidence of exudative AMD is estimated to be between 9.4 per 1000 and 11.4 per 1000 Americans age 65 and older (depending on ascertainment criteria), based on those diagnosed and treated by ophthalmologists for the condition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Women were found to have a slightly higher incidence of AMD than men using all ascertainment criteria (P < 0.001), and white Americans were found to have a fivefold-to-sixfold higher ascertainment criteria than black Americans (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Europe incidence: systematic review and meta-analysis
“In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fellow-eye incidence in untreated unilateral disease
United States annual incident cases by subtype, age, and sex
“This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5). In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 65 years and older the incidence rates of NVAMD within each 5-year age group are higher in women than in men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Share of incident cases expected to be eligible for and able to receive treatment
“Although our overall estimates of NVAMD incidence are high (owing to the inclusion of those at older ages, especially in women), this does not reflect the number in need of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, the inclusion of older ages in our estimates may include a large number who are unwilling or too frail to undergo treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 89% of the US population aged 80 years and older is white.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sensitivity of the fellow-eye incidence estimate to outlier studies
“These cumulative incidence rates were influenced by significant heterogeneity in the studies caused by outliers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If outliers were not included in the analysis, the 12-month incidence rate changed considerably, from 12.2% to 8.1% (95% CI, 4.9–11.9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Neovascular age-related macular degeneration
Global prevalence: systematic review and meta-analysis of 39 population-based studies
“Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence of late-stage AMD in 2019: Vision and Eye Health Surveillance System
“We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence of neovascular AMD or geographic atrophy in 2000
“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States projections and share of severe vision loss
Europe prevalence: systematic review and meta-analysis
Global prevalence of AMD-related vision impairment: Global Burden of Disease Study 2021
“Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04-4·35) in 1990 to 8·06 million (6·71-9·82) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The burden of vision impairment due to AMD is projected to increase to about 21·34 million in 2050.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence of the neovascular subtype and of geographic atrophy
“Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes. Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Projected cases by world region in 2040
“Europe is expected to be second to Asia in the number of projected cases (69 million [40–109] in 2040), followed by Africa (39 million [12–93]), Latin America and the Caribbean (39 million [15–82]), North America (25 million [15–38]), and Oceania (2 million [1–5]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age at which late-stage prevalence rises most steeply
Natural history, survival, and mortality
Natural history: visual acuity loss in untreated eyes
“Mean baseline VA among study patients was 0.64 logarithm of the minimum angle of resolution (logMAR) (approximately 20/87 Snellen). The mean VA change in logMAR progressed from 0.1 (1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (>6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: macular atrophy after untreated neovascular AMD
“The cumulative risks of incident macular atrophy after untreated NV were 9.6% (standard error 1.2%), 31.4% (2.2%), 43.1% (2.6%), and 61.5% (4.3%) at two, five, seven, and 10 years, respectively. This corresponded to a linear risk of 6.5%/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global blindness attributable to AMD
“In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7-18·0]), followed by glaucoma (3·6 million cases [2·8-4·4]), undercorrected refractive error (2·3 million cases [1·8-2·8]), age-related macular degeneration (1·8 million cases [1·3-2·4]), and diabetic retinopathy (0·86 million cases [0·59-1·23]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Legal blindness before and after introduction of anti-VEGF therapy
“The incidence rate of legal blindness attributable to AMD in citizens aged ≥50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI(95)]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity at diagnosis in United States clinical practice
“The study included 162,902 eyes. Among all included eyes, 34.3% presented with 20/40 VA or better at diagnosis. Patients with 20/40 vision or better at baseline maintained a mean VA of 20/40 or better for 2 years after treatment initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: late AMD and all-cause and cardiovascular mortality
“Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of untreated eyes with stable and with worsening acuity
“Several studies reported the proportion of patients categorized as stable (defined as improved or unchanging acuity).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients whose VA worsened (defined generally as any deterioration from baseline) increased from 45.0% at 3 months to 81.1% by 2 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression to legal blindness within three months of presentation
Lesion location and visual prognosis by angiographic subtype in untreated eyes
“In the 41 treatment arms reporting the location of choroidal neovascularization relative to the fovea, most patients had subfoveal disease (81.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on these studies, at 12 months 33.2% (95% CI, 19.3%–48.7%) of patients with occult choroidal neovascularization had lost between 3 and 6 lines of VA, compared with 43.7% (95% CI, 28.0%–60.1%) of patients with classic choroidal neovascularization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This difference was not significant, as reflected by the overlapping CIs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Generalizability of the untreated natural history estimates
Mean visual acuity at diagnosis in first and second eyes
Mortality over three and a half years in a treated trial cohort
Pathophysiology
Macular neovascularization types 1, 2, and 3
“Type 3 neovascularization is to be used when the vascular complex originates in the retina. Type 1 neovascularization is applied when the vessels originate from the choroid and remain under the RPE. Type 2 neovascularization is denoted if neovascularization that originates in the choroid breaks through the RPE to reach the subretinal space.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main causes of vision loss in neovascular AMD include those directly related to the new vessels such as leakage, hemorrhage, and fibrosis. Another important cause of vision loss, particularly in treated cases, is atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VEGF-A and VEGF-C in choroidal neovascularization
“With nAMD, immune cells are recruited to the macula, where they secrete proangiogenic cytokines (e.g., VEGF-A and VEGF-C) and proinflammatory cytokines (e.g., IL-31, LIF, and SDF1α)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These VEGF ligand molecules stimulate endothelial cell proliferation and migration, angiogenesis, and increased vascular permeability, ultimately resulting in leakage of blood vessel fluid that damages the photoreceptor layer and impairs vision” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, hypoxia-induced retinal expression of VEGF-C can induce pathological retinal neovascularization to an extent similar to that of VEGF-A” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Compensatory VEGF-C and VEGF-D upregulation after VEGF-A inhibition
“Other ligand angiogenic mediators, VEGF-C and VEGF-D, are important in the pathogenesis of cancer and retinal vascular diseases; and evidence shows they are upregulated after VEGF-A suppression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a laser-induced mouse model of CNV (a major cause of visual loss in patients with nAMD), the ability of anti-VEGF-C/-D monotherapy to reduce vascular leakage and CNV area was similar to that of aflibercept (which targets VEGF-A/-B and PIGF); and when used in combination, the efficacy was superior to that of either therapeutic approach alone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement dysregulation linked to CFH
Pathogenic processes implicated in drusen formation and photoreceptor degeneration
“Chronic inflammation, lipid deposition, oxidative stress and impaired extracellular matrix maintenance are strongly implicated in AMD pathogenesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the exact interactions of pathophysiological events that culminate in drusen formation and the associated degeneration processes remain to be elucidated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease spectrum of distinct phenotypes with different pathogenic mechanisms
“Compelling progress in high-resolution retinal imaging has enabled refined phenotyping of AMD in vivo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, our current understanding promotes the view that AMD represents a disease spectrum comprising distinct phenotypes with different mechanisms of pathogenesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Optical coherence tomography in diagnosis and management
Optical coherence tomography angiography: diagnostic accuracy for macular neovascularization
Fluorescein angiography indications
Monitoring during anti-VEGF treatment and of high-risk fellow eyes
Pooled accuracy of optical coherence tomography angiography against fluorescein angiography in 553 eyes
“Seven primary studies were included. The quality of the evidence was good.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total population included in the meta-analysis comprised 553 eyes, with a cumulative sensitivity and specificity of 85.9% (95% CI 81.9-89.3%) and 89% (95% CI 83.5-93.2%), respectively, cumulative positive and negative likelihood ratios of 8.36 and 0.15, respectively (95% CI of 3.05-22.890 and 0.09-0.24, respectively), and a cumulative diagnostic odds ratio of 67.21 (95% CI 22.58-200.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evidence obtained does not demonstrate the superiority of OCTA over FA. Its use as a support technique could improve patient flow and reduce the number of FA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Visual symptoms: metamorphopsia, decreased vision, and scotoma
| Symptom listed for initial history | Quoted text |
|---|---|
| Distortion | “Metamorphopsia” |
| Reduced acuity | “Decreased vision” |
| Central field loss | “Scotoma” |
| Light flashes | “Photopsia” |
| Low-luminance function | “Difficulties in dark adaptation” |
Clinical signs: hemorrhage, exudates, subretinal fluid, and fibrosis
Functional impairment: activities of daily living
“The prevalence of impaired basic, instrumental and total ADL was 37.76%, 67.82% and 39.59%, respectively. In multivariate-adjusted models, moderate visual impairment [OR 5.65, 95% CI (2.31-13.83) and blindness [OR 5.43, 95% CI (2.09-14.12)] were associated with greater odds of impaired total ADL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological effects: depressive and anxiety symptoms
“The prevalence of depressive symptoms was 42.04% and 31.78% as per the CES-D-10 and MHI scales, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Qualitative data showed that 56% of patients (n = 132) reported anxiety related to anti-VEGF treatment. The main sources of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment effectiveness, rather than around pain. From validated questionnaires, 17% of patients (n = 52) showed clinical levels of anxiety and 12% (n = 36) showed clinical levels of depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Perceptual symptoms: Charles Bonnet syndrome visual hallucinations
“We found an overall prevalence of CBS of 15.8% (95% confidence interval: 11.0%-21.2%). When looking at consecutively recruited patients with neovascular AMD from the clinic, prevalence of CBS was 7.2% (95% confidence interval: 4.3%-10.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Visual outcomes 5 years after starting anti-VEGF therapy: CATT
“At the 5-year visit, 50% of study eyes had VA 20/40 or better and 20% had VA 20/200 or worse. Mean change in VA was −3 letters from baseline and −11 letters from 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Geographic atrophy was present in 213 (41%) of 515 gradable eyes and was subfoveal in 85 (17%). Among 555 eyes with spectral domain optical coherence tomography, 83% had fluid (61% intraretinal, 38% subretinal, and 36% sub-retinal pigment epithelium).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Geographic atrophy under anti-VEGF treatment
“Among the 1011 participants who did not have GA at baseline and had follow-up images gradable for GA, the cumulative incidence was 12% at 1 year, 17% at 2 years, and 38% at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall GA growth rate was 0.33 (SE, 0.02) mm/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subretinal fibrosis and scar formation
“Cumulative proportion of eyes with scar was 32%, 46% and 56% at year 1, 2 and 5, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 68 eyes that developed fibrotic scar at year 1, visual acuity decreased by a mean of additional 13 letters between year 1 and 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most fibrotic scars and accompanying macular atrophy expanded over time, reducing visual acuity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seven-year outcomes after intensive ranibizumab therapy: SEVEN-UP
“At a mean of 7.3 years (range, 6.3-8.5 years) after entry into ANCHOR or MARINA, 37% of study eyes met the primary end point of 20/70 or better BCVA, with 23% achieving a BCVA of 20/40 or better. Thirty-seven percent of study eyes had BCVA of 20/200 or worse.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active exudative disease was detected by spectral-domain OCT in 68% of study eyes, and 46% were receiving ongoing ocular anti-VEGF treatments. Macular atrophy was detected by FAF in 98% of eyes, with a mean area of 9.4 mm(2); the area of atrophy correlated significantly with poor visual outcome (P<0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Falls and fractures
“Compared with comparators, there was an increased risk of falls in those with cataract (adjusted hazard ratio [HR], 1.36; 95% CI, 1.35-1.38), AMD (HR, 1.25; 95% CI, 1.23-1.27), and glaucoma (HR, 1.38; 95% CI, 1.35-1.41). Likewise for fractures, there were increased risks in all eye diseases, with an HR of 1.28 (95% CI, 1.27-1.30) in the cataract cohort, an HR of 1.18 (95% CI, 1.15-1.21) for AMD, and an HR of 1.31 (95% CI, 1.27-1.35) for glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hip fractures: Medicare beneficiaries
“In adjusted analyses, the risk of hip fractures was similar in cases that were coded with exudative AMD (odds ratio, 1.03; 95% confidence interval (CI), 0.95, 1.12) compared with cases with no AMD but was significantly higher in cases that were coded with atrophic AMD (odds ratio, 1.11; 95% CI, 1.06, 1.16).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Atrophy in eyes treated with anti-VEGF agents: systematic review findings
“All studies confirmed the occurrence of atrophy, and when available, longitudinal data from the included studies demonstrated an increase in atrophy incidence over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, visual acuity loss was noted with foveal atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Uncertainty about whether anti-VEGF treatment causes atrophy
“All studies demonstrated that atrophy occurs in the context of MNV treated with anti-VEGF therapy; however, it is not clear whether anti-VEGF treatment is causative of atrophy versus being associated with atrophy development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The included studies were not designed or powered to assess atrophy as a primary outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Continued VEGF inhibition also may increase atrophy development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contribution of atrophy to long-term vision loss
“It is also noteworthy that atrophy represents only approximately 10% of vision loss related to AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further, in a real-world analysis of anti-VEGF therapy for nAMD, fovea-involved atrophy was the most common cause of long-term vision loss, but represented only 37% of the cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Terminology for atrophy in the presence and absence of neovascularization
“According to Classification of Atrophy Meetings group recommendations, the term geographic atrophy should be used strictly to describe atrophy in the absence of MNV.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the presence of MNV, complete RPE and outer retinal atrophy is preferred when atrophy is defined using OCT, whereas macular atrophy is preferred when atrophy is observed clinically or defined on CFP (with GA being reserved for atrophy in the absence of MNV).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retinal thinning and lesion growth accompanying the five-year decline in acuity
“The proportion of eyes with an abnormally thin retina increased from 22% at the end of Year 2 to 36% at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Worse VA outcomes have also been associated with increased lesion size, and in the Follow-up Study, mean lesion size increased more than 50% over the 3.5 year period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data highlight the need for agents that can prevent or minimize geographic atrophy and expansion of the total neovascular lesion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of returning participants in the five-year follow-up cohort
“Non-participants had a mean age 2.3 years older (p<0.001) and a mean baseline visual acuity score 3.1 letters worse than participants (p=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, the Follow-up Study results are likely better than would have been observed if 100% of CATT patients had returned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Neovascular age-related macular degeneration
Humanistic burden and health-related quality of life
Health utility values by visual acuity in the better-seeing eye
“The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vision-related quality of life: NEI VFQ-25 in a treated clinic cohort
“Individuals with mild or moderate visual impairment or blindness at baseline had significantly lower NEI-VFQ-25 scores at follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those with impaired instrumental ADLs scored 11.62 (p = 0.02), 13.13 (p < 0.0001) and 15.8 (p = 0.0012) points lower in the NEI-VFQ-25, SF-36 physical component score and EQ-5D-5L summary score, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and mental health during anti-VEGF treatment: systematic reviews
“Depression or depressive symptoms were reported in up to 42% of patients with nAMD. Of 25/63 (40%) studies evaluating quality of life (QoL) and using various tools, eight studies reported composite National Eye Institute Visual Functioning Questionnaire scores following anti-VEGF treatment. Of these, seven reported a statistically significant improvement at the earliest time point measured (Month 3-12) and approximately 50% reported sustained QoL benefits at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression and vision-related quality of life in guideline recommendations
Economic burden and healthcare resource utilization
Direct healthcare costs: commercially insured United States population
“Mean (SD) annual total all-cause cost for the prevalent cohort was $24,520 ($43,950) with outpatient costs as the largest cost component” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The nAMD-related outpatient costs represented 28% of total costs and 44% of total outpatient costs, respectively, and were driven primarily by anti-VEGF injection-related costs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual all-cause cost was lower for the incident cohort compared to the prevalent cohort (mean [SD] = $18,943 [$29,236] vs mean [SD] = $24,520 [$43,950], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with active choroidal neovascularization (CNV) incurred at least $7,000 higher all-cause annual costs than patients with inactive CNV or inactive scar, largely driven by higher outpatient/anti-vascular endothelial growth factor (anti-VEGF) costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual visit and injection burden: commercially insured United States population
“Mean (SD) annual nAMD-related outpatient burden was 6.6 (4.8) visits overall; patients with active CNV had the highest utilization compared with patients with inactive CNV or inactive scar (P < 0.0001). Overall mean (SD) annual anti-VEGF–related outpatient visit burden was 3.9 (4.2) visits, with the highest utilization seen in active CNV group compared with inactive CNV and inactive scar groups (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part B anti-VEGF injection volume and reimbursement, 2014 to 2023
“From 2014 to 2023, a total of 36 398 293 intravitreal anti-VEGF injections were administered to Medicare beneficiaries. Aflibercept use increased significantly (618 796 injections in 2014 vs. 1 713 729 in 2023; τ = 0.91; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Standardized Medicare reimbursement per injection declined significantly for ranibizumab ($1234.35-$724.74; τ = -1.00; P < 0.001) and aflibercept ($1527.37-$1379.54; τ = -0.82; P = .001), remained stable for brolucizumab, and increased for bevacizumab ($46.76-$300.73; τ = 0.69; P < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part B anti-VEGF spending per beneficiary
“During this 5-year period, associated Medicare drug costs averaged $1.3 billion annually. The number of Medicare Part B claims for aflibercept increased from 518 836 in 2013 to 866 749 in 2015. Annual Medicare drug expenditure for aflibercept was $1.4 billion on average. On average, Medicare spent $9719 and $9934 annually on each beneficiary receiving ranibizumab and aflibercept injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab and aflibercept costs account for 12% of the Medicare Part B budget annually.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age-related macular degeneration (ARMD) therapies aflibercept and ranibizumab are among the highest-cost Medicare Part B drugs, even though off-label use of lower-cost bevacizumab is clinically noninferior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AMD treatment costs per Medicare fee-for-service beneficiary, 2004 to 2018
Societal costs by visual acuity in the better-seeing eye
“The mean annual societal cost for the Control Cohort was $6,116 and for the Study Cohort averaged $39,910 (P < 0.001). Study Subcohort 1 costs averaged $20,339, while Subcohort 4 costs averaged $82,984.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total societal ophthalmic costs associated with neovascular age-related macular degeneration dramatically increase as vision in the better-seeing eye decreases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs of vision loss and blindness in the United States
“We estimated an economic burden of VL of $134.2 billion: $98.7 billion in direct costs and $35.5 billion in indirect costs. The largest burden components were NH ($41.8 billion), other medical care services ($30.9 billion), and reduced labor force participation ($16.2 billion), all of which accounted for 66% of the total. Those with VL incurred $16 838 per year in incremental burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Informal care was the largest burden component for people 0 to 18 years of age, reduced labor force participation was the largest burden component for people 19 to 64 years of age, and NH costs were the largest burden component for people 65 years of age or older.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinic time burden for staff and patients
Estimated Medicare savings from bevacizumab use
Anti-VEGF agent use across United States payers, 2017 to 2023
Total Medicare expenditure on anti-VEGF therapy, 2014 to 2023
“From an economic perspective, total Medicare expenditures for anti-VEGF therapy rose from approximately $2.5 billion USD in 2014 to $3.7 billion USD in 2023, despite declining reimbursement per injection for aflibercept and ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This increase was primarily driven by rising injection volumes and the introduction of newer branded agents (faricimab and brolucizumab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual Medicare drug cost per treated beneficiary by agent, 2022
“Bevacizumab, despite its widespread use in cost-sensitive settings, contributed minimally to total Medicare expenditures because of its low average cost per dose ($241 USD annually per beneficiary treated for wet age-related macular degeneration in 2022), compared with $8219 USD for aflibercept and $6143 USD for ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Injection rates per 100,000 Medicare beneficiaries by agent, 2014 to 2023
“aflibercept increased from 1864/100 000 to 5997/100 000 beneficiaries (221% rise)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab declined overall by 44%, decreasing from 2437/100 000 to 1359/100 000 between 2014 and 2023, with an interim peak of 2591/100 000 in 2019.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Faricimab increased from 219/100 000 to 1947/100 000 between 2022 and 2023 (789% rise), whereas brolucizumab declined from 142 to 18 per 100 000 (87% decline).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
State-level variation in anti-VEGF injection rates, 2023
“For aflibercept, Alaska recorded the highest injection rate at 68 241/100 000, whereas Hawaii had the lowest at 2602/100 000, resulting in a 26.2-fold difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Faricimab utilization ranged from 207/100 000 in Vermont to 10 247/100 000 in Nebraska, a 49.4-fold difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because the MPUPD data set captures only FFS claims, states with higher MA enrollment have smaller captured FFS denominators, which may inflate calculated per-capita injection rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staff time devoted to neovascular age-related macular degeneration care in retina practices
| Practice total | Quoted value |
|---|---|
| Staff members involved in neovascular AMD care | “23 people”View highlighted excerpt for this quote |
| Office time per week across all staff members | “225 hours”View highlighted excerpt for this quote |
“The present study demonstrated that practices are highly invested in the management of patients with neovascular AMD, with an average retina practice consisting of 23 staff members involved in the disease management for every 1 treating retina specialist.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, the management of patients with neovascular AMD accounts for one-fifth of the staff’s working week, and this estimate may likely underestimate the true workflow based on less structured communications with retina specialists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The management of patients with neovascular AMD accounted for an average of 20% of the staff’s time per work week: most technicians (68%) spent more than 20% of their time, one-quarter of office managers spent more than 10% of their time, and more than one-third (37%) of billing managers spent more than 20% of their time managing patients with neovascular AMD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retina specialist views on monitoring and injection frequency as burdens on staff, materials, and office space
“When asked about the impact of activities for monitoring and injection administration on staff time, the majority of the surveyed retina specialists (62%, 35 of 57) felt that frequency of patient monitoring placed a significant burden on staff time. A large percentage of retina specialists (58%, 33 of 57) felt that billing and filing for reimbursement was also a significant burden on staff resources.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, 42% (24 of 57) of retina specialists considered monitoring frequency to be very impactful on material resources such as drugs and other supplies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-nine percent (28 of 57) of retina specialists reported that the frequency of injections was an impactful burden on office space, including waiting rooms and examination rooms. Over one-third of physicians (35%, 20 of 57) considered frequency of patient monitoring to be an important motivator in choosing a treatment to prescribe. Two-thirds of physicians (38 of 57) stated they would find it very desirable to reduce office visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visit preparation time and post-injection recovery time
“Although these preparatory steps were typically performed concurrently, the average total staff time spent on all preparation steps was 43 minutes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More than one-third (36%, 27 of 75) of patients reported that their most recent visit took 90 minutes or more, and 79% (59 of 75) reported spending at least 3 hours recovering following injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Practice setting and monthly injection volume of the surveyed retina specialists
“There were 57 retina specialists involved in the survey, 68% (39 of 57) were in a group practice, 14% (8 of 57) practiced in an academic setting, and 18% (10 of 57) were solo practitioners.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average total number of patients treated per month in these 3 settings was 556, and the average number of neovascular AMD patients treated per month was 201.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The quantitative research section of this study was conducted between July and November 2011; additional sampling of respondents from Midwest and Great Plains states was carried out from June through August 2012, as these regions were underrepresented in the original sample.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Neovascular age-related macular degeneration on families
Caregiver time and transportation to injection visits
“Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours). Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver work absenteeism: multinational survey including United States caregivers
“Caregivers estimated they provided support for 4.2 ± 2.9 days/week and 6.0 ± 7.1 h/day on average. Nearly half of caregivers (45.6%) reported some impairment in daily activities, and more than two-thirds (70.5%) of working caregivers (n = 44) reported work absenteeism due to anti-VEGF treatment/monitoring appointments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden scores and contributors
“The mean CRA score was 3.2±0.5, similar to the score reported by caregivers for atrial fibrillation who require regular hospital appointments for monitoring their thromboprophylaxis. Caregiver tasks including accompanying for hospital appointments for eye treatment and patient's visual acuity in the better eye were the biggest contributors to the caregiver burden hierarchical model explaining 18% and 11% of the variance respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver costs as a share of societal costs
“Direct nonmedical costs, primarily caregiver, comprised 67.1% of Study Cohort societal ophthalmic costs, versus 21.3% ($1,302/$6,116) of Control Cohort costs (P < 0.001) and 74.1% of 20/800 to no light perception subcohort costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver relationships and treatment barriers
“Many caregivers were a child/grandchild (47%) or partner (23%) of the patient; only 7% were professional caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients and caregivers reported a number of obstacles in managing wAMD, including the treatment itself (35% and 39%, respectively). Sixteen percent of patients also missed a clinic visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transportation to injection visits and the relationship of the accompanying person
“The majority of patients (72%, 54 of 75) were driven to their appointment by a caregiver. Their caregiver was a spouse or partner (65%, 35 of 54), an adult child or grandchild (22%, 12 of 54), a friend (7%, 4 of 54), or another person (6%, 3 of 54).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty percent (15 of 75) of patients drove themselves, while 8% (6 of 75) took a car service or public or government transportation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket transportation costs reported by participants
“Few patients experienced direct out-of-pocket transportation costs. Eighty-nine percent (67 of 75) reported that they did not pay any transportation costs for their latest clinic visit. Among those who had out-of-pocket transportation cost, 12% (8 of 67) paid for parking, 6% (4 of 67) paid tolls, and 3% (2 of 67) paid bus fare.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age, comorbidity, and household income of surveyed participants
“The average age was 79 years (range 55–98 years) and 89% (67 of 75) of patients had a concomitant medical condition. The average income was $40 000. The majority of patients (62%, 46 of 75) reported an income of less than or equal to $50 000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Medicare Physician Fee Schedule payment for OCT, OCTA, and fluorescein angiography, 2025
Frequency of OCT testing: commercially insured United States population
| Annual OCT test-related visits | Overall cohort | Active CNV | Inactive CNV | Inactive scar |
|---|---|---|---|---|
| Patients with at least 1 visit, n (%) | “5,350 (88.1)”View highlighted excerpt for this quote | “3,384 (92.6)”View highlighted excerpt for this quote | “893 (85.4)”View highlighted excerpt for this quote | “253 (70.7)”View highlighted excerpt for this quote |
| Number of unique visits, mean (SD) | “4.5 (3.5)”View highlighted excerpt for this quote | “5.4 (3.6)”View highlighted excerpt for this quote | “2.9 (2.6)”View highlighted excerpt for this quote | “1.6 (1.9)”View highlighted excerpt for this quote |
Medicare savings from OCT-guided anti-VEGF treatment
“From 2008 – 2015, the United States government and nvAMD patients have accrued an estimated savings of $9.0 billion and $2.2 billion, respectively, from the use of OCT to guide personalized anti-VEGF treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic testing patterns in Medicare and claims populations
“In the 2008-2010 cohorts (n = 10 259), mean annual number of injections remained low (bevacizumab: 4.6, 5.1, and 5.5; ranibizumab: 6.1, 6.6, and 6.9), as did mean numbers of ophthalmologist visits (bevacizumab only) and OCT examinations (both agents), but there was no such trend in FA examinations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diffusion of diagnostic tests among Medicare beneficiaries in the first year after diagnosis
“A total of 23 941 Medicare beneficiaries with exudative AMD newly diagnosed during 1992-2009.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current Procedural Technology (CPT-4) billing codes were used to identify use of diagnostic tests (optical coherence tomography, fluorescein angiography, and fundus photography) and therapeutic interventions (argon laser photocoagulation, photodynamic therapy, intravitreal corticosteroids, and anti-vascular endothelial growth factor [VEGF] agents) used by these beneficiaries during the first year following diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diffusion was rapid for each successive new diagnostic and treatment modality, with use of newer procedures quickly replacing existing ones.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although improving patient outcomes, rapid diffusion raises important public policy issues for Medicare and other payers to consider.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Anti-VEGF monoclonal antibodies and antibody fragments
AAO Preferred Practice Pattern: anti-VEGF therapy as first-line treatment
NICE guideline NG82: anti-VEGF treatment and equivalence of agents
Ranibizumab: MARINA sham-controlled phase 3 trial
“We enrolled 716 patients in the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab: ANCHOR trial versus verteporfin photodynamic therapy
“Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab: FDA-labeled dosing intervals
Bevacizumab (off-label): CATT comparison with ranibizumab
“In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab: off-label status and comparative efficacy in the AAO Preferred Practice Pattern
Ranibizumab biosimilars
Brolucizumab: HAWK and HARRIER phase 3 trials
“Patients (N = 1817) with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Greater than 50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing through Week 48 (56% [HAWK] and 51% [HARRIER]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Brolucizumab was noninferior to aflibercept in visual function at Week 48, and >50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing interval through Week 48.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab: retinal vasculitis and retinal vascular occlusion
“Retinal vasculitis and IOI after brolucizumab IVI are characterized by variable occlusion of large or small retinal arteries, or both, and perivenular abnormalities. It may span from peripheral vasculitis to occlusion of large retinal arteries around the optic nerve or macula with severe vision loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab: real-world incidence of intraocular inflammation
“The overall incidence of IOI and/or RO was 2.4% (255 of 10 654 eyes) and 2.4% (268 of 11 161 eyes) for the IRIS and Komodo groups, respectively, and RV and/or RO, 0.6% (59 of 10 654 eyes and 63 of 11 161 eyes), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab: MERLIN every-4-week dosing in persistent fluid
“Incidence of intraocular inflammation (IOI), including retinal vasculitis and retinal vascular occlusion, was 11.5% (0.8% and 2.2%) for brolucizumab versus 6.1% (0% and 0.6%) for aflibercept.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of IOI, including retinal vasculitis and retinal vascular occlusion, was higher with brolucizumab versus aflibercept; therefore, brolucizumab should not be used more frequently than every 8 weeks after the loading regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab intraocular inflammation through 96 weeks: rates and reported event terms
“The incidence of ocular adverse events (AEs) was similar across all treatment groups in both HAWK and HARRIER up to week 96 (Table 1), with the exception of combined intraocular inflammation (IOI) (iritis and uveitis), which was higher in the brolucizumab 6 mg group of HAWK compared with the aflibercept group (4.7% vs. 0.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The AEs related to IOI reported in both studies were iritis, uveitis, anterior chamber cell, anterior chamber flare, anterior chamber inflammation, chorioretinitis, eye inflammation, iridocyclitis, keratic precipitates, retinal vasculitis, vitreous haze, and vitreitis; among these, the most frequently reported were iritis and uveitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with week 48, the incidence of these AEs from week 48 through week 96 was low, with additional cases in HAWK only (2 cases of iritis in the brolucizumab 3 mg group, 1 case in the brolucizumab 6 mg group, and 1 case in the aflibercept group and 1 case of uveitis in the brolucizumab 6 mg group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Disparities between treatment arms were observed in the rates of IOI, 4.4% with brolucizumab versus 0.8% with aflibercept, and of endophthalmitis, 0.7% with brolucizumab versus 0.1% with aflibercept.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retinal artery occlusion with concomitant inflammation in HAWK and HARRIER
“More specifically in relation to ATEs, across both studies, 4 brolucizumab 3 mg patients and 6 brolucizumab 6 mg patients experienced a RAO event that was reported as a SAE in 3 patients in the brolucizumab 3 mg group and in 0 patients in the brolucizumab 6 mg group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All brolucizumab 6 mg patients and 1 of the brolucizumab 3 mg patients showed concomitant IOI either before or after the RAO event.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients with RAO and concomitant IOI, 6 patients lost letters (2, 15, 21, 55, 55, and 62 letters) and 1 patient gained 18 letters by the end of the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endophthalmitis onset relative to injection in HAWK and HARRIER
“All but 1 of the brolucizumab endophthalmitis patients showed onset within 5 days from the last injection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The time to onset since the last active injection and the investigator assessments suggest that it is likely that these endophthalmitis cases were related to the injection procedure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Interval from injection to diagnosis of brolucizumab-associated retinal vasculitis
“Retinal vasculitis and IOI on a per-eye basis were diagnosed at a mean of 30.3 days after brolucizumab IVI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The interval to seeking treatment with vasculitis after the second brolucizumab IVI seemed to be shorter, ranging between 7 and 26 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In eyes with retinal vasculitis after the first brolucizumab injection, this presentation could be delayed as long as 8 weeks after the injection, making a direct toxic or infectious cause unlikely and pointing to an autoimmune event, possibly leading to ischemia as a more likely cause.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical findings and visual acuity at diagnosis in the postmarketing case series
“All eyes showed vitreous cells or opacities, and most (11 eyes [73.3%]) showed anterior chamber cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fine, nongranulomatous keratic precipitates, conjunctival injection, and Descemet folds also were reported, and no case of hypopyon occurred in this series.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 15 eyes, 9 eyes (60%) lost 0.3 logMAR of VA or more (the equivalent of 3 lines or more of ETDRS acuity)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five eyes (33%) showed a VA of less than 20/200.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Management of brolucizumab-associated inflammation and examination before repeat injection
“Treatment consisted of corticosteroids administered by a variety of methods (topical, sub-Tenon, oral, intravitreal, or a combination thereof).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients underwent vitrectomy without improvement of vision.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Repeat brolucizumab IVI is contraindicated in an eye with active IOI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It also means that a clinical examination should be considered (rather than using a direct-to-injection protocol) before repeating brolucizumab injections to confirm that no IOI or vasculitis are present.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Continued examinations are indicated in eyes demonstrating solely IOI because the occlusive vasculitis may develop after the initial examination.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior anti-VEGF exposure and the reason for switching in affected eyes
“The number of previous anti-VEGF IVIs ranged between 2 and 80 in the affected eye before switching to brolucizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nine patients were switched to brolucizumab for persistent intraretinal fluid, subretinal fluid (SRF), or both, and 3 patients were switched for potential increased durability of brolucizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inflammation with other approved anti-VEGF agents and the limits of incidence estimates
“Although IOI has been reported with the other FDA-approved anti-VEGF agents, most notably aflibercept, it typically is mild and sterile and resolves with corticosteroid eye drops.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of retinal vasculitis cannot be ascertained because it is also not known how many injections of brolucizumab have been administered nationwide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
IVAN two-year comparison of ranibizumab with bevacizumab and of continuous with discontinuous dosing
“Between March 27, 2008, and Oct 15, 2010, we randomised 628 patients to ranibizumab or bevacizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (−1·63 letters, –4·01 to 0·75; p=0·18).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It is now established that bevacizumab is not inferior to ranibizumab after 2 years of either continuous or discontinuous treatment with respect to visual acuity” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Safety was worse when treatment was administered discontinuously.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
VEGF trap fusion proteins
Aflibercept 2 mg: VIEW 1 and VIEW 2 phase 3 trials
“Patients were randomized to intravitreal aflibercept 0.5 mg monthly (0.5q4), 2 mg monthly (2q4), 2 mg every 2 months after 3 initial monthly doses (2q8), or ranibizumab 0.5 mg monthly (Rq4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a prespecified integrated analysis of the 2 studies, all aflibercept regimens were within 0.5 letters of the reference ranibizumab for mean change in BCVA; all aflibercept regimens also produced similar improvements in anatomic measures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These studies demonstrate that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 2 mg: FDA-labeled dosing
Aflibercept 8 mg: PULSAR 48-week results
“PULSAR is a phase 3, randomised, three-group, double-masked, non-inferiority, 96-week trial conducted across 223 sites worldwide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aflibercept 8 mg showed efficacy and safety with extended dosing intervals, which has the potential to improve the management of patients with nAMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 8 mg: PULSAR 96-week results
“Least squares (LS) mean change from baseline in BCVA at week 96 was +5.6 (95% confidence interval [Cl], 4.1-7.1), +5.5 (95% Cl, 4.0-7.0), and +6.6 (95% Cl, 5.2-8.0) letters in the 8q12, 8q16, and 2q8 groups, respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients completing 96 weeks of treatment in the 8q12, 8q16, and 2q8 groups received a mean of 9.7, 8.2, and 12.8 active injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 87% of patients in the 8q12 group had last assigned dosing intervals of 12 weeks or more, whereas 78%, 53%, and 31% of patients in the 8q16 group qualified for last assigned dosing intervals of ≥ 16 weeks, ≥ 20 weeks, and 24 weeks, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 2 mg biosimilars
Bispecific Anti-VEGF/Angiopoietin-2 antibodies
Faricimab: TENAYA and LUCERNE primary results
“Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6·0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2·0 mg every 8 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab: two-year results with treat-and-extend dosing
“At week 112 in TENAYA and LUCERNE, 59.0% and 66.9%, respectively, achieved Q16W faricimab dosing, increasing from year 1, and 74.1% and 81.2%, achieved Q12W or longer dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients achieving extended dosing intervals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab: injection counts and inflammation in the AAO Preferred Practice Pattern
Faricimab: FDA-labeled dosing and retinal vasculitis warning
Port delivery system with ranibizumab
Archway phase 3 trial: refill-exchange every 24 weeks versus monthly ranibizumab
“Patients with nAMD diagnosed within 9 months of screening previously treated with and responsive to anti-vascular endothelial growth factor therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Archway enrolled 418 patients; 251 were randomized to and 248 received treatment with the PDS Q24W, and 167 were randomized to and received treatment with monthly ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Archway met its primary objective and PDS Q24W demonstrated noninferior and equivalent efficacy to monthly ranibizumab, with 98.4% of PDS-treated patients not receiving supplemental treatment in the first 24-week interval.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FDA-labeled indication and boxed warning for endophthalmitis
Surgical implantation, voluntary recall, and market reintroduction
Portal extension trial: long-term safety
“In the All-PDS safety population (mean follow-up, 111 weeks), 137 (24.7%) patients had ≥1 ocular AESI; most common were cataract (11.4%), vitreous hemorrhage (6.1%), and conjunctival thickening (bleb)/filtering bleb leak (6.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 95% of patients did not need supplemental treatment before each refill-exchange for >2 years since Portal enrollment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endophthalmitis cases across PDS clinical trials
“Seven cases (7/11 [63.6%]) had preceding/concurrent conjunctival complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At last follow-up, 7 patients recovered vision to study baseline levels or ≥20/40; 4 patients experienced vision loss of ≥15 ETDRS letters.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Photodynamic therapy and thermal laser photocoagulation
Verteporfin photodynamic therapy: TAP trials
“At the month-12 examination, 246 (61%) of 402 eyes assigned to verteporfin compared with 96 (46%) of 207 eyes assigned to placebo had lost fewer than 15 letters of visual acuity from baseline (P<.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Verteporfin: FDA-labeled indication
Current role of photodynamic therapy and thermal laser in the AAO Preferred Practice Pattern
NICE guideline NG82: photodynamic therapy
Photodynamic therapy combined with ranibizumab in polypoidal choroidal vasculopathy: EVEREST II
“At 12 months, mean improvement from baseline was 8.3 letters with combination therapy vs 5.1 letters with monotherapy (mean difference, 3.2 letters; 95% CI, 0.4-6.1), indicating that combination therapy met the predefined criterion for noninferiority as well as being superior to monotherapy (P = .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 12 months, the combination therapy group received a median of 4.0 ranibizumab injections compared with 7.0 in the monotherapy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Current standard of care for neovascular AMD consists of repeated intravitreal anti-VEGF injections that suppress, but do not cure, the disease. Labeled maintenance intervals range from every 4 weeks (ranibizumab) to every 8 to 16 weeks (aflibercept 8 mg, faricimab); in PULSAR, participants completing 96 weeks received a mean of 8.2 to 12.8 injections, and through year 2 of TENAYA and LUCERNE the median number of faricimab injections was 10. Outcomes in routine practice are lower than in trials. In 49,485 treatment-naive eyes in a United States retina database, a mean of 7.3 injections in year 1 produced a mean gain of 0.95 letter, and in an 8-country study of 2,227 patients, mean injections fell from 5.0 in year 1 to 2.2 in year 2, with mean gains of +2.4 and +0.6 letters. In one United States practice, 2,003 of 9,007 patients (22.2%) were lost to follow-up after anti-VEGF injections, and a systematic review reported that up to 50% of patients stopped treatment by 24 months. Visits are time intensive: a time-and-motion study reported an average of almost 12 hours per visit from the patient perspective, including recovery. Long-term vision declines despite treatment: in the CATT cohort, mean visual acuity at 5 years was 3 letters below baseline and 11 letters below the 2-year value, and in SEVEN-UP macular atrophy was present in 98% of study eyes at a mean of 7.3 years. Longer-acting options carry specific risks: brolucizumab labeling warns of retinal vasculitis and retinal vascular occlusion, and the port delivery system requires surgical implantation, carries a boxed warning for an up to 3-fold higher rate of endophthalmitis than monthly ranibizumab (11 of 555 patients, 2%), and was voluntarily recalled in 2022 before reintroduction in 2024. Branded anti-VEGF agents account for a large share of Medicare Part B drug spending; ranibizumab and aflibercept accounted for 12% of the Part B budget in 2011 to 2015.
Real-world undertreatment and visual outcomes in the United States
“At 1 year, after a mean of 7.3 anti-VEGF injections, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for change in VA, +0.77 to +1.13 letter; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Real-world nAMD patients receive fewer anti-VEGF injections and experience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomized controlled trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Older patients and those with poor baseline VA may be particularly prone to undertreatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world injection frequency and loss of initial visual gains: multi-country study
“Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In clinical practice, fewer injections are administered than in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world treatment falls short of trial protocols
Nonadherence, nonpersistence, and loss to follow-up
“Nonpersistence occurred early, with up to 50% of patients stopping treatment by 24 months. High rates of nonadherence were similarly reported, occurring in 32% to 95% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 9007 patients (mean [SD] age, 81.2 [8.8] years; 5917 [65.7%] female; 7905 [87.8%] white), 2003 (22.2%) were LTFU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LTFU rates ranged from <5% to >75% over up to 10 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who were LTFU had worse visual outcomes even after resuming care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time burden on patients, caregivers, and practices
“An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours). Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term decline in vision despite treatment
“Vision gains during the first 2 years of the trial were not maintained at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean change in VA was -3 letters from baseline and -11 letters from 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Macular atrophy was present in 98% of study eyes, the mean area increasing from 0.83 ± 0.96 mm(2) at the ANCHOR or MARINA year 2 exit to 2.22 ± 1.6 mm(2) at the SEVEN-UP visit, a growth rate of 0.28 mm(2)/year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor-described limitations of bolus anti-VEGF injections
Unresolved challenges for gene therapy approaches
“Although promising, challenges including long-term safety, complex delivery procedures, immune responses, regulatory hurdles, and the need for optimized vectors and clinical protocols must be addressed before widespread adoption and integration into standard care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Injection frequency and atrophy: conflicting analyses across trials
“The 2-year CATT analysis revealed an increased association between atrophy incidence and frequent treatment and also demonstrated a reduced incidence from year 1 to 2 among patients switched from monthly to PRN treatment; at the 5-year visit, the differences were no longer significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, follow-up analyses of HARBOR and IVAN revealed no difference in atrophy incidence with monthly or continuous versus PRN or discontinuous treatment, in contrast with initial findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For example, when images from HARBOR were analyzed with SD OCT, no difference in atrophy with monthly versus PRN was noted, in contrast with previous findings on CFP or FA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reducing injection frequency because of atrophy concern carries a risk of vision loss
“Reducing the frequency of anti-VEGF therapy to allay concerns of atrophy could lead to vision loss; however, titration, or dose adjustment, could be used to mitigate concerns about atrophy development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because undertreatment of MNV is deleterious to vision, caution should be taken when extending treatment intervals because of concern regarding atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No treatment for atrophy currently exists; therefore, physicians rely on cues from atrophy phenotype and risk factors when making treatment decisions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
4D-150 is investigational and has no established place in therapy. The sponsor describes its intended role as a single, in-office intravitreal "backbone therapy" that would replace repeated anti-VEGF injections rather than extend dosing intervals. The phase 3 4FRONT trials define the population studied for registration: 4FRONT-1 (North America) enrolls adults aged 50 years or older with treatment-naive macular neovascularization secondary to AMD, and 4FRONT-2 (global) enrolls treatment-naive participants and participants previously treated with no more than 4 anti-VEGF injections who were diagnosed no more than 6 months before screening. Both trials require a demonstrated clinical response to aflibercept, BCVA of 25 to 78 ETDRS letters, and central subfield thickness of 500 microns or less, with aflibercept 2 mg as the comparator; target enrollment is 480 participants per trial. By comparison, the approved sustained-delivery option (the port delivery system) is labeled for patients who previously responded to at least 2 anti-VEGF injections and requires surgical implantation, whereas 4D-150 is given by intravitreal injection, the same route used for current anti-VEGF agents. In the PRISM phase 1/2 trial, the sponsor also enrolled participants with severe, recalcitrant disease and high injection burden, a population in which use could be considered if approved. Current anti-VEGF care is delivered by ophthalmologists, predominantly retina specialists, in the office setting and billed under Medicare Part B; 36,398,293 intravitreal anti-VEGF injections were administered to Medicare beneficiaries from 2014 to 2023. Payer utilization management already applies to this class: after step therapy implementation in Medicare, relative use of aflibercept increased by 32.0% and bevacizumab decreased by 33.2%, and in 9 retina practices 96.2% of 2,225 prior authorization requests were approved but 59.6% of approvals delayed care by more than 24 hours. The sponsor reports that CMS has not established a uniform coverage and reimbursement policy for genetic medicine products.
Sponsor-intended role: in-office backbone therapy
Studied populations: 4FRONT phase 3 program and PRISM
4FRONT-1 eligibility: treatment-naive disease with response to aflibercept
4FRONT-2 eligibility: treatment-naive or recently diagnosed, previously treated disease
Comparator positioning: sustained-delivery implant labeled after response to prior injections
Care setting: ophthalmologist-administered office care
Medicare Part B utilization of intravitreal anti-VEGF agents
“From 2014 to 2023, a total of 36 398 293 intravitreal anti-VEGF injections were administered to Medicare beneficiaries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Faricimab demonstrated rapid early uptake after its introduction in 2022 (65 052-556 512 injections).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Payer utilization management: step therapy and prior authorization
“After step therapy implementation, relative usage of aflibercept increased by 32.0%, while there was a decrease in relative usage of bevacizumab by 33.2% and ranibizumab by 4.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step therapy has not significantly increased bevacizumab usage on an aggregate level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 2140 (96.2%) requests were approved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 2140 approvals, 59.6% (1277) resulted in a delay in care greater than 24 hours, and 40% (863) were given on the date of service.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Coverage uncertainty for genetic medicines
Care setting and payer mix of anti-VEGF injection encounters, 2017 to 2023
“Encounters where a patient received an intravitreal injection in an ophthalmology clinic were categorized by intravitreal medication ordered, visit diagnosis, and primary insurance payor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NAMD was the most common diagnosis at 53.2% (311672/585056 total diagnoses across all encounters), followed by diabetic eye diseases at 26.9% (157187/585056), retinal vascular occlusion at 14.4% (84442/585056)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“53.7% of encounters listed Medicare as the primary payor (309130/575256 total primary payors), while commercial/miscellaneous insurance covered 40.2% (231570/575256), and Medicaid covered 3.44% (19780/575256).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Agent selection rates in neovascular age-related macular degeneration and by payer
“In patients with nAMD, aflibercept 2 mg was used at a mean rate of 353.5 per 100000 OE (SD = 101.8) followed by bevacizumab at 202.8 (SD = 32.3) [t(6)=5.35, p = 0.002] and ranibizumab 0.5 mg at 62.9 per 100000 OE (SD = 16.6) [t(6) = 6.62, p < 0.001] from 2017–2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with Medicare (including both Medicare Advantage and part B [traditional fee-for-service Medicare]) insurance most often received aflibercept 2 mg at significantly higher rates than bevacizumab (M = 364.3/100000 OE, SD = 109.7 vs M = 187.1/100000 OE, SD = 28.4, respectively) [t(6) = 5.67, p = 0.001].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with commercial insurance, there was no significant difference in the average rate of use of aflibercept 2 mg (M = 233.9/100000 OE, SD = 94.9) and bevacizumab (M = 197.9/100000 OE, SD = 56.2) [t(6)=2.07, p > 0.05].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adoption of a newly approved agent and stated demand for reduced treatment burden
“We observed a rapid adoption of faricimab, which surpassed the utilization of ranibizumab after less than 2 years following FDA approval in January 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While our results demonstrate that aflibercept 2 mg and bevacizumab remain the most utilized agents overall across all indications, there is a strong demand for the development of agents with greater or equivalent therapeutic efficacy with less treatment and/or financial burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Billing code availability as a constraint on use of a high-cost agent
“Aflibercept 8 mg was approved late in our study and does not have a permanent J code as of March 1, 2024 for billing, which limits physicians from utilizing a high-cost medication for concerns of denied reimbursement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Step therapy under Medicare Advantage: treatment switching and injection frequency in a single practice
Heterogeneity of treatment effect
Variability in response to anti-VEGF therapy and definitions of response
“There are significant inter-individual differences in response to an anti-VEGF agent, made more complex by the availability of multiple anti-VEGF agents with different molecular configurations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response to anti-VEGF therapy have been found to be dependent on a variety of factors including patient's age, lesion characteristics, lesion duration, baseline visual acuity (VA) and the presence of particular genotype risk alleles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non-response is defined as an increase in fluid (IRF, SRF and CRT), or increasing haemorrhage compared with the baseline and/or loss of >5 letters compared with the baseline or best corrected vision subsequently.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline predictors of visual outcome and injection need: HARBOR
“Baseline predictors of BCVA change from baseline at M12 and/or percentage of 3-line gainers included lower BCVA, younger age, smaller total choroidal neovascularization (CNV) leakage area, smaller area of occult CNV, and presence of subretinal fluid (SRF).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic background and choice of agent
Polypoidal choroidal vasculopathy subtype
“Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative age-related macular degeneration among Asian individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy was also superior to monotherapy in achieving complete polyp regression at month 12 (69.3% vs 34.7%; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (95% CI) change from baseline to weeks 40/44/48 average was +8.9 (7.3-10.5) letters for BCVA and -126.5 (-144.8 to -108.3) μm for CST.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 48, 83.4% (105/126) of patients were on ≥ Q12W dosing and 53.2% (67/126) were assigned to Q20W dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline disease severity and extended dosing with aflibercept 8 mg
Real-world differences in treatment intensity by age and baseline vision
“Greater mean 1-year change in VA also trended with worse baseline VA; those patients with better VA at presentation tended to be particularly vulnerable to vision loss. Those who received the fewest injections tended to be older and have worse baseline VA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup differences in brolucizumab inflammation risk
“Patients with a history of IOI and/or RO in the 12 months before brolucizumab initiation had an increased observed risk rate (8.7% [95% CI, 6.0%-11.4%] and 10.6% [95% CI, 7.5%-13.7%]) for an IOI and/or RO event in the 6 months following the first brolucizumab treatment compared with patients without prior IOI and/or RO (2.0% in both data sets).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
4D-150 PRISM: comparators used for burden reduction differ by cohort
Subgroup efficacy results for 4D-150 by lesion subtype, genotype, or race
No evidence found.
Preexisting neutralizing antibody titers as a determinant of response and eligibility
“A critical consideration in future clinical development is the establishment of NAb threshold cutoffs to refine patient selection and increase trial success rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The implementation of standardized assays and validated NAb titer thresholds, exemplified by AAV6 enrollment assays that, through analyses of clinical trial data, demonstrate a correlation between preexisting NAb levels and transgene expression, enables more precise stratification of patients into likely responders and non-responders, thereby optimizing trial enrollment and minimizing variability in clinical outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transient immunosuppression to broaden eligibility in antibody-positive participants
“Combination therapy, such as transient systemic or local immunosuppression, represents a promising approach to enhance efficacy and expand patient eligibility in AAV-based gene therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This strategy can attenuate anti-capsid immune responses and has shown potential to enable transduction in NAb-positive subjects, and its use is increasingly explored in clinical settings” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion phenotype and risk factors for atrophy during anti-VEGF treatment
“Key risk factors or phenotypes associated with atrophy were fellow eye atrophy, reticular pseudodrusen, increased injections, and type 3 lesion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These phenotypes may explain why not all patients with AMD have the same atrophy-related outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For example, patients with type 3 lesions typically demonstrate atrophy in parallel with anti-VEGF treatment; however, those with other lesion types may not demonstrate atrophy as readily with anti-VEGF therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sex distribution among reported cases of brolucizumab-associated retinal vasculitis
“From review of patient characteristics, all 12 patients in this series were women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although this may be chance, a greater preponderance of noninfectious uveitis and autoimmune disorders occur in women, and this may play a role.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Two-year visual outcomes by baseline visual acuity in United States registry practice
“In all groups, eyes with better VA at baseline retained better VA at both Years 1 and 2” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only groups of eyes with a mean VA of 20/40 or better at baseline maintained 20/40 or better vision 2 years after treatment initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eyes with baseline VA of 37 to 23 letters (20/200-20/320) showed the greatest gain in VA at Year 1, improving to 0.37 ± 0.64 logMAR (20/160), and to 0.38 ± 0.68 logMAR (20/160) at Year 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, mean VA declined slightly in the those with greater than 82 letters at baseline, from 0.03 ± 0.08 logMAR (> 20/25) to 0.14 ± 0.25 logMAR (20/32) at Year 1 and 0.18 ± 0.31 logMAR at Year 2 (20/32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Racial composition and follow-up completeness of the registry cohort
“It should be noted that 97.5% of the evaluated population was white (which may not reflect the current racial makeup of the United States); the overwhelming percentage of white patients in this analysis suggests white patients may be more likely to seek diagnosis and treatment, or it may be reflective of socioeconomics and access to eye care in more racially diverse locations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further, our 2-year data included only 54% of those included at baseline” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
AAO Preferred Practice Pattern: treatment regimens and follow-up
Monthly versus as-needed dosing: CATT
“Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monthly versus as-needed dosing: HARBOR
“However, all treatment groups demonstrated clinically meaningful visual improvement (+8.2 to +10.1 letters) and improved anatomic outcomes, with the PRN groups requiring approximately 4 fewer injections (6.9-7.7) than the monthly groups (11.2-11.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend versus monthly dosing: CANTREAT
“By the end of month 24, 466 of the 580 randomized patients (80.3%) had completed the study and participants in the T&E arm received a mean of 17.6 injections compared with 23.5 injections for the monthly arm, for a difference of 5.9 injections and visits over 2 years (95% CI, 5.4-6.5; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) BCVA improvement was not worse with the T&E arm, 6.8 (14.1) letters vs 6.0 (12.6) letters, compared with the monthly arm (difference, 0.9; 95% CI, -1.6 to 3.3; P = .21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend versus PRN in the third year: TREX-AMD
Regimen and long-term outcomes in routine practice
“Eyes from ANZ patients received more injections than eyes from Swiss subjects over 10 years (a median of 53 vs 42, respectively) from fewer visits with better disease control (proportion of visits with active disease: 38% vs 69%, respectively), suggesting a treat-and-extend regimen versus a pro re nata regimen (treatment given only when the lesion is active).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Structured regimens and retention in care
“Treat-and-extend (T&E) regimens showed lower LTFU than pro re nata.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Interventions to improve access and personalize support are essential to reduce LTFU and preserve visual outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline NG82: switching, observation, and stopping treatment
Management of poor or non-response
“Poor or non-response to anti-VEGF treatments requires re-evaluation of diagnosis and if necessary switch to alternative therapies including other anti-VEGF agents and/or with photodynamic therapy (PDT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Supplemental aflibercept in the 4FRONT trials
Visits and injections in years three through five after treatment initiation
“The mean (SD) number of visits for AMD care between the end of the clinical trial and the Follow-up Study visit was 25.3 (13.3); with 8.0 (4.0) in Year 3, 7.2 (4.0) in Year 4, and 6.5 (4.0) in Year 5. The mean (SD) number of treatments was 15.4 (12.5) with 4.8 (4.0) in Year 3, 4.5 (3.8) in Year 4, and 4.0 (3.6) in Year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 96 (14.8%) patients who had no treatments between the end of the clinical trial and the Follow-up Study visit, with a mean (SD) of 12.5 (8.4) visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment intensity and five-year visual outcome across cohorts
“In the Australian retrospective review, the mean number of injections over 5 years was 25 with mean visual acuity decreasing to 20/63.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the mean number of injections was 11 over 5 years in the Pan-American Study and the mean visual acuity at 5 years was 20/250.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, more frequent treatment, both in the initial 2 years and in later years appears associated with better long-term outcomes, and many patients require treatment through 5 years and beyond.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switching between anti-VEGF agents after release from a trial protocol
“After release from the clinical trial protocol, more than half of the patients received a treatment other than the drug assigned to them in the clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 328 patients assigned to ranibizumab, 46 (14.0%) had no treatments, 64 (19.5%) had treatments with only ranibizumab, and 218 (66.5%) had at least 1 other type of treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Injection burden of continuous compared with discontinuous dosing over two years
“Participants assigned to the continuous regimen were treated monthly thereafter.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If retreatment was needed, a further cycle of three doses was given monthly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Regimen | Median number of treatments over 2 years (interquartile range) |
|---|---|
| Continuous, every month | “23 (21 to 24)”View highlighted excerpt for this quote |
| Discontinuous, as needed | “13 (8 to 17)”View highlighted excerpt for this quote |
| Overall | “18 (12 to 23)”View highlighted excerpt for this quote |
Trade-offs between continuous and discontinuous dosing
“Mortality was lower with continuous than discontinuous treatment (OR 0·47, 95% CI 0·22–1·03; p=0·05)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled data from the two trials shows that discontinuous treatment was inferior to continuous treatment for best corrected visual acuity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, the risk of geographic atrophy increased with continuous treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The increased risk of systemic SAEs and death with discontinuous treatment should probably outweigh the increased risk of new geographic atrophy that was recorded with monthly treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous treatment also avoids the need to monitor disease activity on every visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, in the context of biological therapies, the possibility of immunological sensitisation with intermittent dosing needs to be considered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The association of monthly treatment with an increased rate of development of geographic atrophy was more consistent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the IVAN study, 34% of eyes that received continuous (monthly) treatment developed geographic atrophy as compared with 26% in the discontinuous (PRN) group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
With current anti-VEGF therapy, the expected outcome in pivotal trials is prevention of moderate vision loss in most treated eyes and a mean BCVA gain in the first year, followed by maintenance with continued treatment. In MARINA, mean BCVA increased by 7.2 letters with monthly ranibizumab 0.5 mg versus a 10.4-letter decrease with sham at 12 months; in ANCHOR, 96.4% of eyes receiving ranibizumab 0.5 mg lost fewer than 15 letters versus 64.3% with verteporfin. Newer agents achieve similar mean gains with fewer injections: at 2 years, adjusted mean BCVA change with faricimab was +3.7 and +5.0 letters in TENAYA and LUCERNE, with 59.0% and 66.9% of participants on every-16-week dosing at week 112, and at 96 weeks in PULSAR, least squares mean BCVA change was +5.6 and +5.5 letters with aflibercept 8 mg every 12 and 16 weeks versus +6.6 letters with aflibercept 2 mg every 8 weeks. The port delivery system maintained vision with 98.4% of participants needing no supplemental injection in the first 24-week interval, and Portal interim data suggest maintenance for 4 years in a small cohort. Long-term outcomes are lower. At 5 years in CATT, 50% of eyes had visual acuity of 20/40 or better and mean acuity was 3 letters below baseline; at 7.3 years in SEVEN-UP, mean acuity was 54 letters; and in the Fight Retinal Blindness! registry, eyes in Australia and New Zealand that completed 10 years of treatment lost a mean of 0.9 letters with a median of 53 injections, whereas Swiss eyes lost 14.9 letters with a median of 42. In routine care, outcomes are closer to maintenance than gain (mean +0.95 letter at 1 year in a United States database). The sponsor's stated goals for 4D-150 are maintenance of vision with substantially reduced treatment burden after a single injection, and the 4FRONT primary endpoint is noninferiority of BCVA change to aflibercept 2 mg every 8 weeks at 52 weeks.
Prevention of vision loss and first-year gains in pivotal ranibizumab trials
“At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The benefit in visual acuity was maintained at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Maintenance of vision with extended dosing: faricimab and aflibercept 8 mg
“The BCVA change from baseline at 2 years was comparable between faricimab and aflibercept groups in TENAYA (adjusted mean change, +3.7 letters [95% confidence interval (CI), +2.1 to +5.4] and +3.3 letters [95% CI, +1.7 to +4.9], respectively; mean difference, +0.4 letters [95% CI, -1.9 to +2.8]) and LUCERNE (adjusted mean change, +5.0 letters [95% CI, +3.4 to +6.6] and +5.2 letters [95% CI, +3.6 to +6.8], respectively; mean difference, -0.2 letters [95% CI, -2.4 to +2.1]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aflibercept 8 mg delivered sustained disease control in patients with nAMD, maintaining improvements in visual and anatomic outcomes through week 96 with extended dosing intervals and similar safety profile to aflibercept 2 mg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability with continuous delivery: port delivery system
“Interim results from Portal suggest 4-year maintenance of visual/anatomic outcomes with PDS 100 mg/mL, with the PDS preferred to monthly injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of Ladder-to-Portal previous monthly ranibizumab patients, 92% preferred the PDS over injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term visual outcomes: CATT at 5 years
“At the 5-year visit, 50% of study eyes had VA 20/40 or better and 20% had VA 20/200 or worse.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, 50% of eyes had VA 20/40 or better, confirming anti-VEGF therapy as a major long-term therapeutic advance for neovascular AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term visual outcomes: SEVEN-UP at 7 years
Long-term visual outcomes: 10-year registry data
“The mean VA in 132 eyes (28%) from ANZ patients who completed 10 years of treatment dropped by 0.9 letters from baseline (95% confidence interval [CI], -4.9 to 3.1; P = 0.7) with 42% achieving ≥20/40, whereas the 37 eyes (12%) from Swiss subjects lost 14.9 letters (95% CI, -24 to -5.7; P < 0.001) with 35% achieving ≥20/40.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eyes with nAMD may achieve satisfactory long-term visual outcomes if they receive adequate treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term outcomes in polypoidal choroidal vasculopathy
Expected outcomes for 4D-150: phase 3 primary endpoint
Maintenance of every-12-week brolucizumab dosing through 96 weeks
“The probability that an eye could be maintained on an q12w interval after loading to the DAA at week 92 was 39.7% and 45.4% for the brolucizumab 3 mg and 6 mg treatment groups in HAWK, respectively, and 38.6% for the brolucizumab 6 mg group in HARRIER.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those eyes receiving treatment q12w at the week 44 DAA in HAWK, an 80.5% (brolucizumab 3 mg) and 81.5% (brolucizumab 6 mg) probability of remaining on an q12w interval until the final DAA at week 92 was found, whereas the probability was 75.4% for the brolucizumab 6 mg group in HARRIER.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Starting at week 16 (the first DAA), and up to week 92 (the last DAA), HAWK had 8 DAAs and HARRIER had 14 DAAs at which patients could only be adjusted from q12w to q8w therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity maintained to week 96 and the effect of high baseline acuity
“These BCVA gains, comparable across treatment arms and studies, were maintained until week 96, with both the brolucizumab 6 mg group and the aflibercept group gaining between 5.3 and 6.6 ETDRS letters from baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These visual acuity gains may have been influenced by a ceiling effect resulting from a high mean baseline BCVA of 60 ETDRS letters (60.6 letters [HAWK] and 61.2 letters [HARRIER], resulting from the upper limit of 78 letters for the BCVA inclusion criterion).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Interpretation limit on the reported every-12-week proportion
“Unlike real-world clinical practice, eyes in the brolucizumab treatment group that were switched from q12w to q8w therapy based on a DAA were not permitted to move back to q12w treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As a consequence, the probability for patients to remain on an q12w regimen at week 96 may be underestimated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration of anti-VEGF expression reported across AAV gene therapy programs
Visual outcomes before anti-VEGF therapy as a benchmark
Expected gain in eyes with poor baseline vision
“Only eyes with 20/200 or less at baseline exhibited a gain in mean VA following treatment, yet these groups were only able to reach the still significantly limited VA of 20/160 after 2 years of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote